CAMP4 THERAPEUTICS CORPORATION CAMP
4.20 USD -0.13 (-3.00%)
At closeNov 11, 2026, 4:01 PM EST
4.20 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
4.14 Day range 4.42
2.90 52-week range 7.75
- YTD
- -31.48%
- 1 year
- +1.69%
News
marketbeat.com CAMP4 Therapeutics Targets 2028 for Key SYNGAP1 Trial Data CAMP4 Therapeutics NASDAQ: CAMP expects data from its Phase 1/2 study of CMP-002, its experimental treatment for SYNGAP1-related disease, in the first half of 2028, CEO Josh Mandel-Brehm said during…
marketbeat.com CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears CAMP4 Therapeutics NASDAQ: CAMP expects initial data from its SYNGAP1 clinical program in the first half of 2028, as the company prepares to begin dosing patients with a treatment designed to…
zacks.com CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.55 per share a year ago.
benzinga.com Camp4 Therapeutics Q3 EPS $(0.37) Misses $(0.18) Estimate, Sales $1.899M Beat $1.850M Estimate Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.18) by 105.56 percent. This is a 32.73 percent increase over losses…
globenewswire.com CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to…
zacks.com CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com CAMP4 Therapeutics Receives CTA Approval From Regulatory Authorities And Ethics Committees Of Multiple EU Countries To Initiate Global Phase 1/2 ASCEND Clinical Trial Of CMP-002 At Trial Sites In European Union Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002Company…
globenewswire.com CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union Approval under the EU Clinical Trials Regulation builds on CAMP4's recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company's global Phase 1/2 trial of CMP-002
benzinga.com Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10 Raymond James analyst Tiago Fauth initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and announces Price Target of $10.
marketbeat.com CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease Korro and Tevard outlined approaches designed to expand the therapeutic use of RNA medicines beyond protein silencing, highlighting programs that aim to repair genetic defects or restore production…- benzinga.com Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8 Needham analyst Joseph Stringer initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $8.
globenewswire.com CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference WATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory…
defenseworld.net CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated “Moderate Buy” by Wall Street Brokerages CAMP4 Therapeutics Corporation (NASDAQ: CAMP - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat…- benzinga.com Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6 Chardan Capital analyst Keay Nakae maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Buy and lowers the price target from $6.5 to $6.
defenseworld.net CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002 CAMP4 Therapeutics (NASDAQ: CAMP) said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results…
seekingalpha.com Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
marketbeat.com CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002 CAMP4 Therapeutics NASDAQ: CAMP said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
benzinga.com CAMP4 Therapeutics Receives MHRA Authorization To Include UK Sites In Global Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic Candidate For Patients With SYNGAP1-Related Disorder Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and…
globenewswire.com CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4's recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina
benzinga.com CAMP4 Therapeutics To Host Virtual Analyst Day To Demonstrate CMP-002 Data To Treat SYNGAP1-Related Disorder CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene…
globenewswire.com CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory…
globenewswire.com CAMP4 to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of…
thenewswire.com Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Québec Vancouver, British Columbia – TheNewswire - August 31, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) (“ Canadian GoldCamps ” or the “ Company ”) announces that, further to its…
thenewswire.com Canadian GoldCamps Enters into Agreement to Acquire Stealthwall West Gold Project in Northeastern Québec Vancouver, British Columbia – TheNewswire - August 18, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) is pleased to announce that it has entered into a definitive property…
benzinga.com Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15 Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.
zacks.com CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.62 per share a year ago.
benzinga.com Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.21) by 176.19 percent. This is a 6.45 percent increase over losses…
globenewswire.com CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth…
cnbc.com CAMP4 advances rare disease treatment for SYNGAP1 into human trials CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 trial of CMP-002, its experimental ASO therapy for SYNGAP1-related disorders. The trial will enroll at…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
benzinga.com CAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorderRegulatory milestone enables Company to raise up to $50 million through…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares moved upwards by 24.0% to $1.71 during Wednesday's after-market session. The market value of their outstanding shares is at $135.0 million. Medpace…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Advanced Biomed (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market session. The market value of their outstanding shares is at $8.2 million. Barinthus Biotherapeutics…
benzinga.com W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey.…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Top analysts upgraded XOM, CAMP, EXR, WPC, and KRC stocks, with price targets ranging from $44 to $154. See other analysts' views on these stocks.- benzinga.com JP Morgan Upgrades Camp4 Therapeutics to Overweight, Raises Price Target to $9 JP Morgan analyst Anupam Rama upgrades Camp4 Therapeutics (NASDAQ:CAMP) from Neutral to Overweight and raises the price target from $5 to $9.
- benzinga.com Chardan Capital Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $6.5 Chardan Capital analyst Keay Nakae initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $6.5.
- benzinga.com Camp4 Therapeutics Q1 EPS $(0.32) Misses $(0.29) Estimate, Sales $1.294M Beat $300.000K Estimate Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 48.39 percent increase over losses…
- benzinga.com CAMP4 Therapeutics Submits Reprint To bioRxiv Titled "Profiling and Targeting of Regulatory RNAs to Upregulate Gene Expression." Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously…
- benzinga.com Rodman & Renshaw Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $7 Rodman & Renshaw analyst Seema Sheoran initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $7.
benzinga.com Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday Wall Street analysts changed outlook on top names. See complete view of rating changes, including upgrades/downgrades, on our analyst ratings page.- benzinga.com Leerink Partners Maintains Outperform on Camp4 Therapeutics, Raises Price Target to $9 Leerink Partners analyst Mani Foroohar maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform and raises the price target from $8 to $9.
benzinga.com Camp4 Therapeutics Earnings Review: Q4 Summary - benzinga.com Camp4 Therapeutics Q4 EPS $(0.87) Misses $(0.30) Estimate, Sales $348.000K Miss $538.000K Estimate Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.30) by 190 percent. This is a 12.99 percent decrease over losses of…
benzinga.com GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.- benzinga.com UPDATE: CAMP4 Therapeutics Partners With GSK To Develop ASO Therapies For Neurodegenerative And Renal Diseases; Secures $17.5M Upfront Collaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseasesCAMP4 to receive $17.5 million upfront and…
- benzinga.com CAMP4 Therapeutics Prices $30M Underwritten Offering Of 5M Shares At $6.00 Each CAMP4 Therapeutics Corporation ("CAMP4" or the "Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session